Results 81 to 90 of about 44,893 (265)

Mesenchymal Stem Cells From a Klinefelter Syndrome Patient: Functional Characterization and Therapeutic Implications

Andrology, EarlyView.
ABSTRACT Background Cell therapy, particularly those utilizing mesenchymal stem/stromal cells (MSCs), is gaining traction as a therapeutic option for regenerative treatment in patients with limited therapeutic options. Although the safety of MSC‐based interventions is well established, uncertainties remain regarding how genetic abnormalities and ...
Marzena Zychowicz, Wioletta Lech, Anna Figiel‐Dabrowska, Marta Kot, Magdalena Murzyn, Natalia Malawska, Barbara Pienkowska‐Grela, Zuzanna Sandowska‐Markiewicz, Iwona Ziolkowska‐Suchanek, Agnieszka Zimna, Tomasz Oldak, Natalia Rozwadowska, Anna Sarnowska   +12 more
wiley   +1 more source

Neoplastic Risk in Patients With Klinefelter Syndrome

Andrology, EarlyView.
ABSTRACT Background Besides gonadal involvement (hypogonadism, male factor infertility, and testicular hypotrophy), patients with Klinefelter syndrome (KS) may suffer from several extra‐gonadic complications, including neoplastic events. Objective The aim of this review is to summarize all major clinical evidence dealing with the association between KS
Andrea Graziani, Giuseppe Grande, Riccardo Selice, Antonella Di Mambro, Alberto Ferlin   +4 more
wiley   +1 more source

P343: GENOMIC CHARACTERISATION OF B-OTHER ALL IN UKALL2003 PATIENTS BY NEXT GENERATION SEQUENCING

HemaSphere, 2022
C. Schwab, R. Cranston, S. Ryan, E. Butler, E. Winterman, Z. Hawking, M. Bashton, J. Murray, A. Enshaei, J. Gibson, A. Vora, A. Moorman, C. Harrison   +12 more
doaj   +1 more source

Day‐30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation

British Journal of Haematology, EarlyView.
Summary While plasma‐derived proteins have emerged as potential biomarkers for prognosis after haematopoietic stem cell transplantation (HSCT), there are insufficient data assessing if established proteins interleukin 1 receptor‐like 1 (IL1RL1), chemokine ligand 9 (CXCL9) and regenerating islet‐derived 3‐α (REG3α) retain their utility in the mismatched
Trent Wang, Anna C. Ferreira, Nasheed M. Hossain, Denggang Fu, Elizabeth G. Hill, Antonio M. Jimenez Jimenez, Cara Benjamin, Krishna V. Komanduri, Sophie Paczesny   +8 more
wiley   +1 more source

Transplantation outcomes in patients with Down syndrome‐associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies

British Journal of Haematology, EarlyView.
This nationwide study of 56 patients with Down syndrome‐associated acute lymphoblastic leukaemia (ALL) demonstrated that haematopoietic stem cell transplantation (HSCT) in complete remission (CR)1/2 yields comparable event‐free survival to non‐Down syndrome ALL.
Hisashi Ishida, Yasuhiro Okamoto, Hirotoshi Sakaguchi, Yasuyuki Arai, Tomoaki Ueda, Shunsuke Yamamoto, Mio Yano, Tomoko Yokosuka, Keiko Okada, Maho Sato, Shuhei Karakawa, Ryoji Kobayashi, Keisuke Kato, Katsuyoshi Koh, Toshihiro Fujiki, Kumiko Goi, Shoji Saito, Junko Takita, Takako Miyamura, Yuhki Koga, Nao Yoshida, Atsushi Sato, Moeko Hino, Ken Tabuchi, Yuki Arakawa   +24 more
wiley   +1 more source

Next-generation Sequencing and Karyotype Analysis for the Diagnosis of Robertsonian Translocation Type Trisomy 13: A Case Report

Iranian Journal of Public Health, 2017
Trisomy 13 (Patau syndrome) is the third most common autosomal trisomy with a prevalence between 1 in 10,000 - 20,000 live births. Robertsonian translocations represent the largest number of chromosomal aberrations in human population with an incidence ...
Jing SHA, Fumin LIU, Bei ZHANG, Yang HUANG, Qinglin ZHANG, Gao JUAN, Jingfang ZHAI   +6 more
doaj  

Cesni‐cel (ARI0002h) in ultra‐high‐risk multiple myeloma with plasma cell leukaemia or central nervous system involvement

British Journal of Haematology, EarlyView.
ARI0002h induced response in 15/17 patients with plasma cell leukaemia (PCL)/central nervous system (CNS)‐multiple myeloma (MM) (87% achieved ≥ very good partial response [VGPR]) with a median progression‐free survival (PFS)/overall survival (OS) of 10.5 and 15.9 months respectively.
Carlos Jimenez‐Mira, Natalia Tovar, Núria Martínez‐Cibrián, Verónica González‐Calle, Nil Albiol, Nieves López‐Muñoz, Aina Oliver‐Caldés, Azucena González, José Miguel Mateos, Marta Español‐Rego, Laura Rosiñol, Manel Juan, Paola Charry, José María Sanchez‐Pina, Sergio Navarro, Daniel Munárriz, Lucía López‐Corral, Valentín Ortiz‐Maldonado, Sara Varea, Eulalia Olesti, Julio Delgado, Álvaro Urbano‐Ispizua, Joaquín Martínez‐López, María Victoria Mateos, Luis Gerardo Rodríguez‐Lobato, Carlos Fernández de Larrea   +25 more
wiley   +1 more source

Mesomelia-synostoses syndrome: contiguous deletion syndrome, SULF1 haploinsufficiency or enhancer adoption?

Molecular Cytogenetics
Background Mesomelia-Synostoses Syndrome (MSS)(OMIM 600,383) is a rare autosomal dominant disorder characterized by mesomelic limb shortening, acral synostoses and multiple congenital malformations which is described as a contiguous deletion syndrome ...
Ingrid Bendas Feres Lima, Lúcia de Fátima Marques de Moraes, Carlos Roberto da Fonseca, Juan Clinton Llerena Junior, Mana Mehrjouy, Niels Tommerup, Elenice Ferreira Bastos   +6 more
doaj   +1 more source

Implementation of the Fluorescent in Situ Hybridization technique in the Faculty of Medicine, UdelaR

Anales de la Facultad de Medicina, 2017
The Cytogenetic Laboratory of the Faculty of Medicine processes, on average, 300 annual samples of public and private healthcare centers by conventional cytogenetics.
Andrea Cairus, Eugenia Choca, Florencia Savio, Vanina Silva, Catherin Vera, Faride Uturbey   +5 more
doaj  

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

British Journal of Haematology, EarlyView.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile, Vanessa Innao, Salvatrice Mancuso, Enrica Antonia Martino, Antonio Mosca, Giovanna Motta, Francesca Pedalino, Marco Rossi, Fabio Stagno, Giorgio Tona, Francesco Di Raimondo, Giuseppe Alberto Palumbo   +21 more
wiley   +1 more source